Ipragliflozin – 250 mg

Brand:
Cayman
CAS:
761423-87-4
Storage:
-20
UN-No:
Non-Hazardous - /

Ipragliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 7.4 nM in CHO cells expressing the human cotransporter).{49504} It is selective for SGLT2 over SGLT1, SGLT3, SGLT4, SGLT5, and SGLT6 (IC50s = 1.9, 30.4, 15.9, 0.46, and 10.4 µM, respectively). Ipragliflozin (0.1-3 mg/kg) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in a mouse model of diabetes induced by high-fat diet, streptozotocin (STZ; Item No. 13104), and nicotinamide (Item No. 11127).{49505} It decreases plasma and hepatic IL-6, TNF-α, chemokine (C-C motif) ligand 2 (CCL2), and C-reactive protein (CRP) levels in the same model when administered at a dose of 3 mg/kg per day for 28 days.  

 

Out of stock

SKU: 22287 - Category:

Description

A SGLT2 inhibitor (IC50 = 7.4 nM in CHO cells expressing the human cotransporter); selective for SGLT2 over SGLT1, SGLT3, SGLT4, SGLT5, and SGLT6 (IC50s = 1.9, 30.4, 15.9, 0.46, and 10.4 µM, respectively); decreases plasma levels of insulin and glucose in an oral glucose tolerance test in a mouse model of diabetes induced by high-fat diet, STZ, and nicotinamide from 0.1-3 mg/kg; decreases plasma and hepatic IL-6, TNF-α, CCL2, and CRP levels in the same model at 3 mg/kg per day for 28 days


Formal name: (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol

Synonyms:  ASP1941

Molecular weight: 404.5

CAS: 761423-87-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Immunology & Inflammation